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BACKGROUND/PURPOSE: The yeast Kodamaea ohmeri rarely causes life-threatening human infections. 
However, risk factors, laboratory diagnoses, and treatments for K. ohmeri infection have been limited, and 
the optimal therapy for K. ohmeri infection has not been identified.
METHODS: Twenty cases of K. ohmeri infection have been reported in the English medical literature. 
We present two new cases of K. ohmeri fungemia. We investigated the nature and treatment of K. ohmeri 
infections using minimum inhibitory concentrations of antifungal agents and by comparing the two 
cases with those described in the literature.
RESULTS: From March 1998 to December 2008, a total of 22 patients with K. ohmeri infections were 
studied. Hematological malignancies and diabetes were the most common co-morbidities for K. ohmeri 
infections, with crude prevalence rates of 27.3% and 18.2%, respectively. The K. ohmeri isolates showed less 
susceptibility to fluconazole but greater susceptibility to amphotericin B [15/25 isolates (60%) vs. 25/25 
isolates (100%), respectively]. Good outcomes (8/9 cases; 88.9%) were found following removal of indwelling 
catheters and implants. In addition, voriconazole and echinocandins, such as caspofungin and micafungin, 
also showed excellent minimum inhibitory concentrations against K. ohmeri.
CONCLUSION: K. ohmeri should not be regarded as a contaminant of blood cultures. Favorable outcomes 
for this potentially life-threatening infection are promoted by the removal of indwelling catheters; further-
more, outcomes are associated with optimal antifungal regimens, especially voriconazole and echinocandins.
KEYWORDS: echinocandins, fluconazole, fungemia, Kodamaea ohmeri, voriconazole
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Introduction
Fungi are being increasingly recognized as major patho-
gens in critically ill patients. Candida spp., Aspergillus spp., 
and Cryptococcus spp. comprise the majority of isolates in 
invasive fungal infections.1,2 Other yeasts and filamen-
tous fungi, such as Blastomyces dermatitidis, dematiaceous 
fungi, Coccidioides spp., Fusarium spp., Histoplasma capsu-
latum, Scedosporium spp., Trichosporon spp., Penicillium spp., 
and Zygomycetes are emerging as significant human 
pathogens.2,3 Over the past decades, Kodamaea ohmeri 
has been recognized as an opportunistic pathogen, es-
pecially in immunocompromised patients.4 This fungus 
has been rarely reported in the medical literature pub-
lished since 1970. This report presents two new patients 
with a K. ohmeri infection that occurred within the same 
hospital service, and a review of previously reported 
cases.
Methods
We conducted a search (using the MEDLINE database) 
of the English medical literature from January 1970 
to December 2008 using the following keywords: Pichia, 
Kodamaea ohmeri, and yeast. We found 20 reported cases 
of K. ohmeri infection.4–16 Here, we report two new cases of 
K. ohmeri fungemia, one with concomitant cellulitis.
Case 1
A 71-year-old man was admitted to our hospital with fever, 
disturbance of consciousness, and cellulitis in his right 
leg. He had type 2 diabetes, coronary artery disease, iatro-
genic Cushing’s syndrome, major depression, and post-
surgical herniation of an intervertebral disc in the lumbar 
spine. On admission, his body temperature was 39.3ºC, 
heart rate was 84 beats/min; respiratory rate was 24 breaths/
min, and blood pressure was 130/80 mmHg. Physical 
examination revealed erythema and swelling of his right 
leg. A complete blood cell count showed a white cell count 
of 7 × 109/L with 74.9% neutrophils, and a C-reactive pro-
tein level of 78 mg/L. Blood biochemistry showed glucose 
was 14.4 mmol/L, triglycerides 8.1 mmol/L, and uric acid 
487.7 umol/L. All other parameters were normal. The 
findings of urine analysis, chest radiograph, and an elec-
trocardiogram were normal. The patient was empirically 
administered intravenous oxacillin for the treatment of 
his cellulitis. A yeast-like organism was isolated from the 
patient’s blood, and he was given intravenous fluconazole 
(400 mg/day). Transthoracic echocardiography showed 
no evidence of vegetation of the cardiac valves. The yeast 
was identified as K. ohmeri. The patient remained febrile 
despite fluconazole therapy; therefore, the antifungal regi-
men was changed to amphotericin B deoxycholate (0.5 mg/
kg/day). Two weeks after this new treatment, the cellulitis 
in his right leg improved and subsequent blood cultures 
were negative.
Case 2
A 58-year-old woman was admitted to our hospital with 
dysphagia and a weight loss of 10 kg in the previous 3 weeks. 
She had a history of esophageal squamous cell carcinoma 
with multiple metastases, including brain, lung, and liver. 
On admission, her body temperature was 37ºC, heart rate 
was 84 beats/min, respiratory rate was 19 breaths/min, 
and blood pressure was 120/90 mmHg. Her blood white 
cell count was 10.2 × 109/L with 74.0% neutrophils. On 
the 3rd day of hospitalization, she was given a percuta-
neous endoscopic gastrectomy and underwent placement 
of a peripherally inserted central catheter into the left 
basilic vein. On the 17th day of hospitalization, the patient 
was given intravenous imipenem-cilastatin to treat pneu-
monia in her left lung. Her fever resolved after therapy, 
but it recurred on the 28th day of hospitalization. A yeast-
like organism was isolated from her blood, and intrave-
nous fluconazole (400 mg/day) was started. The yeast was 
identified as K. ohmeri and was susceptible to fluconazole. 
The same yeast was isolated from her blood on the 38th 
day of hospitalization. The patient died on the 45th day 
of hospitalization. However, the last blood culture, per-
formed 1 day before the patient died, showed no growth 
of K. ohmeri.
Mycological studies
Blood cultures from the two cases were performed using 
the BacT/ALERT Microbial Detection System (bioMèrieux 
SA, Marcy-l’Etoile, France). The isolates from the cases were 
identified in our laboratory via morphological (Sabouraud-
Dextrose agar, Corn Meal agar, and CHROMagar) and bio-
chemical methods (Vitek 2 YST, bioMèrieux, Hazelwood, 
Mo, USA). The susceptibility to antifungal agents was tested 
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using the ATB Fungus 3 system (bioMèrieux SA, Marcy-
l’Etoile, France) according to the manufacturer’s instructions.
In 2007, the Clinical and Laboratory Standards Institute 
[CLSI; formerly the National Committee for Clinical 
Laboratory Standards (NCCLS)] published an approved 
reference method for broth microdilution testing (CLSI 
document M27-A3) of yeasts.17 This method was devel-
oped through a consensus process to facilitate agreement 
among laboratories in determining the susceptibility of 
yeasts to several antifungal agents. The acceptable percent 
essential agreement for minimum inhibitory concentra-
tions (MICs) was set at ≥ 90% for each antifungal agent 
against all organisms tested. Reference MICs were deter-
mined after 48 hours of incubation. The breakpoints in 
the antifungal susceptibility testing of yeasts, as defined 
by the CLSI, showed MICs of ≤ 1, ≤ 8, ≤ 0.125, ≤ 1, ≤ 2, ≤ 2 
and ≤ 4 mg/L, to amphotericin B, fluconazole, itracona-
zole, voriconazole, caspofungin, micafungin, and flucyto-
sine, respectively.17
Results
From March 1998 to December 2008, a total of 22 patients 
with K. ohmeri infections, including the present cases, were 
enrolled in this study. The yeast morphotype in the present 
cases showed white-rough colonies on Sabouraud-Dextrose 
agar plates, and underwent a change from pink to blue on 
CHROMagar plates (Figure). The demographic data and 
clinical characteristics of patients with K. ohmeri infection 
are listed in Table 1.
Sixteen males and six females (i.e. male-to-female ratio 
of ~3:1) were enrolled. The ages ranged from a newborn 
baby to 84 years, with the mean age being 42 years. Infections 
included fungemia (19 cases, with 1 cellulitis, 1 phlebitis, 
2 endocarditis, and 4 catheter infection cases; and 3 cases 
involving children), polymicrobial wound infection (1 case), 
urinary tract infection (1 case) and peritonitis (1 case). 
Hematological malignancy and diabetes were the two most 
common co-morbidities (27.3% and 18.2%, respectively). 
Other reported predisposing factors included neutrope-
nia (4 cases), malignant solid tumors (3 cases), infant (3 
cases), renal failure (2 cases), organ transplantation (1 case), 
hemochromatosis (1 case), and intravenous drug use 
(1 case). The presence of indwelling catheters or implants 
was an important risk factor associated with K. ohmeri 
infection, and removal of these catheters and implants 
was critical for successful management (8/9 cases; 88.9%).
The MICs of the antifungal agents used to treat the 
K. ohmeri strains isolated from the enrolled cases are shown 
in Table 2. Of the drugs tested, 60% of the isolates (15/25) 
showed MICs of ≤ 8 mg/L for fluconazole, and 100% of 
the isolates (25/25) demonstrated MICs of ≤ 1 mg/L for 
amphotericin B; these are the reference breakpoints. Most 
cases treated with fluconazole therapy had poor responses 
or outcomes (12/15 cases; 80%). In addition, more than 
three-quarters (10/13 cases; 76.9%) of the patients who re-
ceived amphotericin B-based therapy (either alone, or as-
sociated with flucytosine, or fluconazole) had favorable 
outcomes. Furthermore, the extended-spectrum antifun-
gal agents, triazole and echinocandins, were found to have 
A B
Figure. Appearance of Kodamaea ohmeri on (A) Sabouraud-Dextrose agar and (B) CHROMagar plates.
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Table 1. Clinical characteristics of Kodamaea ohmeri infection in English medical literatures and the present cases
Case Age (yr) Sex
 Underlying condition(s)/ Source of Catheter status/ Drug
 Outcome Reference
   risk factor(s) culture prosthetic implants therapy
1 48 F Diabetes, kidney transplant Blood CVC, not removed Flu, AmB Expired  4
2a 38 F AML, hemochromatosis,  Blood,  Peripheral catheter,  Flu, AmB Recovered  5
   neutropenia catheter removed
3 59 M VP shunt infection,  Blood,  Peripheral catheter,  AmB Recovered  6
   nosocomial pneumonia phlebitis removed
4 11 M Burkitt’s lymphoma,  Blood CVC Flu Expired  6
   neutropenia
5 41 M Alcoholic ketoacidosis,  Blood CVC – Recovered  6
   tuberculosis
6 47 M Pneumonia, diabetes,  Blood CVC AmB, Flu Expired  6
   chronic renal failure
7 4 F Tetralogy of Fallot  Blood CVC AmB, Flu Expired  6
8 0 F Infant Blood Umbilical artery – Recovered  6
   and vein catheter
9 58 F CML Blood,  HDLC, removed AmB Recovered  7
   catheter tip
10 0 F Infant Blood – AmB, Flu Recovered  8
11 0 M Encephalitis Blood – Flu Expired  9
12 10 M ALL, neutropenia Blood CVC AmB Recovered  9
13 14 M ALL, neutropenia Blood,  PAC, removed Flu Recovered 10
   catheter tip
14 75 M Fibrous histiocytoma Wound – Flu Expired 10
   with wound
15 42 M MV endocarditis, IVDU,  Blood,  VR FC, AmB Recovered 11
   hepatitis C vegetation
16 73 M Hodgkin lymphoma Urine Urinary catheter Flu Recovered 12
17 84 M SCC of sinus Blood,  CVC, removed Flu, AmB Recovered 13
   catheter tip
18 76 M Prosthetic MV endocarditis,  Blood,  VR; pacemaker Flu, AmB Recovered 14
   pacemaker vegetation removed
19 71 M TV endocarditis, pacemaker,  Blood,  CVC, removed AmB Expired 15
   diabetes catheter tip
20 64 M Peritoneal dialysis Peritoneal Tenckhoff catheter,  Flu, AmB Recovered 16
   fluid removed
21 71 M Cellulitis, diabetes, iatrogenic Blood Peripheral catheter,  Flu, AmB Recovered Present
   Cushing syndrome removed  case
22 48 M SCC of esophagus,  Blood PICC Flu Expired Present
   nosocomial pneumonia   case
aCase 2 is reported by Shin DH et al, 2003 [6]. ALL = Acute lymphoblastic leukemia; AmB = amphotericin B; AML = acute myeloid leukemia; 
CML = chronic myelogenous leukemia; CVC = central venous catheter; FC = flucytosine; Flu = fluconazole; HDLC = Hickmann double-lumen 
catheter; IVDU = intravenous drug user; MV = mitral valve; PAC = Port-a catheter; PICC = peripherally inserted central catheter; SCC = squa-
mous cell carcinoma; TV = tricuspid valve; VP shunt = ventriculoperitoneal shunt; VR = valve replacement.
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Table 2. Antifungal susceptibility testing results for Kodamaea ohmeri isolates from cases in English medical literatures and the 
present study
Case Isolate no. Source AmB Flu Itra Vori Casp Mica FC Reference
1 1-1 Blood – – – – – – – 4
2a 2-1 Blood – – – – – – – 5
 2-2 Catheter – – – – – – – 
3 3-1 Blood 0.50  4 0.125 0.06 0.25 0.06 – 6
 3-2 Blood 0.50  4 0.125 0.06 0.25 0.06 – 
 3-3 Phlebitis site 0.50  4 0.125 0.06 0.125 0.06 – 
4 4-1 Blood 0.25 32 0.50 0.50 0.125 0.03 – 6
 4-2 Catheter 0.25 32 0.50 0.50 0.125 0.03 – 
 4-3 Blood 0.50 32 0.50 0.50 0.125 0.03 – 
5 5-1 Blood 0.25 16 0.25 0.125 0.25 0.06 – 6
 5-2 Blood 0.25 16 0.25 0.125 0.25 0.06 – 
6 6-1 Blood 0.25  4 0.125 0.125 0.125 0.03 – 6
 6-2 Catheter 0.25  4 0.125 0.03 0.125 0.03 – 
 6-3 Blood 0.50  4 0.125 0.03 0.125 0.03 – 
7 7-1 Blood 0.25 16 0.125 0.06 0.125 0.03 – 6
8 8-1 Blood 0.50  2 0.125 0.03 0.125 0.03 – 6
9 9-1 Blood 0.50  4 – – – – – 7
 9-2 Catheter – – – – – – – 
10 10-1 Blood 0.064 32 0.25 – – – < 0.002 8
 10-2 Blood – – – – – – – 
11 11-1 Blood 0.008  8 – – – – – 9
12 12-1 Blood 0.008  8 – – – – – 9
13 13-1 Blood 0.50 32 0.25 – – – – 10
14 14-1 Wound 1.00 32 0.008 – – – – 10
15 15-1 Vegetation – – – – – – – 11
16 16-1 Urine Sus Sus Sus – – – Sus 12
17 17-1 Blood – – – – – – – 13
 17-2 Catheter – – – – – – – 
18 18-1 Vegetation 0.25  4 0.03 – – – ≤ 0.125 14
19 19-1 Blood – – – – – – – 15
20 20-1 Peritoneal fluid – – – – – – – 16
21 21-1 Blood 0.50 64 0.50 – – – < 0.50 Present case
22 22-1 Blood 0.50  8 0.125 0.125 – – < 4 Present case
 22-2 Blood 0.50  8 0.125 0.125 – – < 4
 22-3 Blood 0.50  8 0.125 0.125 – – < 4
aPatient 2 is reported by Shin DH et al, 2003 [6]. AmB = Amphotericin B; Casp = caspofungin; FC = flucytosine; Flu = fluconazole; Itra = itraconazole; 
Mica = micafungin; Sus = reported as “susceptibility” only; Vori = voriconazole.
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MICs of ≤ 0.50 (16/16; 100%), ≤ 0.25 (13/13; 100%), and 
≤ 0.06 (13/13; 100%) mg/L to voriconazole, caspofungin, 
and micafungin, respectively. These are excellent MICs in 
comparison to the reference standards.
Discussion
The epidemiology of yeast infections has undergone 
significant changes over the last several decades,2 and the 
annual incidence of fungemia has increased since the 1980s. 
The yeast K. ohmeri, previously known as Pichia ohmeri 
or Yamadazyma ohmeri, belongs to the Saccharomycetaceae 
family.18 The first documented case was in an immuno-
compromised patient with K. ohmeri fungemia, reported 
in March 1998.4 It was first classified as Endomycopsis 
ohmeri19 and later transferred to the genus Pichia by Hansen.20 
K. ohmeri has been placed in the guilliermondii-fibuligera 
group.21
The epidemiology of invasive fungal infections in hu-
mans has changed significantly in the past decade. This is 
probably due to the use of broad-spectrum antibiotic ther-
apy and antifungal prophylaxis, especially in hematologic 
patients.1 K. ohmeri is an emerging opportunistic patho-
gen in clinical practice, and it should not be regarded as 
a contaminant of blood cultures. Although the most 
common risk factors for fungal infection have mainly 
been described in immunocompromised patients,3 there 
is limited data on the risk factors, laboratory analysis, 
treatment, and prevention of K. ohmeri infection. From 
our review, K. ohmeri infections mainly occur in immuno-
compromised patients,4–10,12–13,15,16 and less frequently in 
immunocompetent patients.6,11 In addition, indwelling 
catheters and implants are important risk factors associ-
ated with K. ohmeri infections.4–7,9,10,12–16
Most yeasts are identified on the basis of carbohydrate 
assimilation and/or fermentation, and their macroscopic 
and microscopic morphological features after growth on 
specialized media. Two assays for yeast identification 
are the commercially available Vitek and API 20C assays. 
Although the API 20C assay is considered to be the gold 
standard for identification of K. ohmeri and other yeast 
species, a high false-positive rate with regard to K. ohmeri 
has been reported.6 CHROMagar Candida chromogenic 
growth medium is an extremely useful tool for the identi-
fication of K. ohmeri and Candida species. This assay is based 
on the growth of colored colonies.6 On a CHROMagar 
plate, K. ohmeri colonies undergo a characteristic change 
from pink to blue.6,9,12 This unique characteristic is a simple 
and useful tool for the detection of K. ohmeri.
Because of the poor prognosis for patients with invasive 
fungal infections, optimal treatments and/or antifungal 
strategies are important. Antifungal treatments include 
fluconazole, amphotericin B, or flucytosine, and these 
treatments can be combined with catheter removal, valve 
replacement, and surgical debridement (Table 1). Various 
antifungal regimens have been used to treat K. ohmeri 
infections, but fluconazole therapy has often been associ-
ated with poor responses and poor outcomes.4–6,9,10,13,14,16 
While the optimal treatment for K. ohmeri infections are 
yet to be determined, our review shows good outcomes 
after removal of the indwelling catheters, pacemakers, and 
vegetated cardiac valves.5–7,10,13,14,16 Furthermore, K. ohmeri 
seems to be resistant to fluconazole but is susceptible to 
amphotericin B.22 In addition to these antifungal agents, 
the expanded-spectrum antimicrobials triazole, voricona-
zole, and the echinocandins, caspofungin and micafungin, 
have shown excellent MICs against K. ohmeri in previous 
reports and in our patients (Table 2); however, clinical 
experience with these agents in this setting is lacking.
In conclusion, K. ohmeri can cause life-threatening 
infections. Favorable outcomes for this potentially life-
threatening fungal infection are likely to be associated 
with early diagnosis, optimal antifungal regimens, and 
the removal of indwelling catheters. It should be pointed 
out that fluconazole is the least effective against K. ohmeri 
infections. Although further study is needed to establish 
the optimal antifungal regimens, voriconazole and echi-
nocandins are suggested in treating K. ohmeri infections.
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